Our primary focus is to harness the groundbreaking potential of stem cell technology, aiming to radically transform the approach to treating various cardiovascular diseases.

By developing innovative stem cell-based therapies, we aim to fundamentally change the treatment of heart diseases, offering new, effective solutions for a range of cardiovascular conditions. Our work is not just about research; it’s about leading a healthcare revolution, where advanced science meets hope, and where each discovery brings us closer to saving and improving countless lives.

  • Induced Pluripotent Stem (iPS) Cells
  • Embryonic Stem (ES) Cells
  • Endothelial Stem Cells
  • Mesenchymal Stem Cells
  • Bone Marrow-Derived Multipotent Stem Cells (BMSC)
  • CD31+ Cells
  • Hematopoietic Stem Cells

Our research includes investigating the in vitro differentiation of pluripotent stem cells into endothelial cells, cardiomyocytes, and lymphatic vessels, exploring their therapeutic potential in targeted diseases.

Integrating biomaterial technologies with stem cell applications for enhanced cardiac repair.

  • Heart conditions such as myocardial infarction and chronic heart failure.
  • Peripheral vascular diseases, including PAOD (peripheral artery obstructive disease).
  • Diabetic neuropathy, lymphedema, and wound healing.

Our studies also explore the role of angiogenesis in diabetic complications and investigate functional defects in stem or progenitor cells in diabetes, developing strategies to counteract these impairments.

  • First demonstration of successful gene therapy with VEGF-C for treating secondary lymphedema (Yoon et al., J Clin Invest,2003)
  • Unveiling the role of VEGF and EPCs in diabetic cardiomyopathy (Circulation, 2005).
  • First demonstration of side effects (calcification) of infarcted myocardium treated with unfractionated bone marrow cells (Yoon et al., Circulation, 2004)
  • Development of novel bone marrow-derived stem cells and demonstration of successful therapeutic effects in myocardial infarction (Yoon et al., J Clin Invest, 2005)
  • Investigating the role of host cells in adult stem cell therapy (J Exp Med, 2007).
  • First demonstration of bone marrow-derived EPCs engraft diabetic nerves and improve nerve function in diabetic neuropathy. First demonstration of robust long-term (more than 12 weeks) of adult progenitor cells in diabetic tissues(Jeong et al., Circulation, 2009)
  • First demonstration that CD31+ cells derived from bone marrow and peripheral blood have robust neovascularization effects and highly effective for treating cardiovascular disease (Kim et al., J Am Coll Cardiol, 2010; Kim et al., Circ Res, 2010)